Table 2.
Ongoing relevant trials
| Trial | Country | Phase | RCT | Regimen | Primary endpoint | No of planned pts | PS | Study start date | Registration no |
| Front-line setting | |||||||||
| Canadian group | Canada | 2/3 | Yes | Cis-pem±pembrolizumab | OS | 126 | 0–1 | 07/10/16 | NCT02784171 |
| CM743 | Global | 3 | Yes | Nivolumab/ipilimumab versus p-pem | OS | 606 | 0–1 | 25/10/16 | NCT02899299 |
| PrE0505 | USA | 2 | No | Cis-pem/durvalumab | OS | 55 | 0–1 | 13/06/17 | NCT02899195 |
| JME-001 | Japan | 2 | No | Cis-pem/nivolumab | OR | 18 | 0–1 | 20/01/18 | UMIN000030892 |
| Salvage setting | |||||||||
| Confirm | UK | 3 | Yes | Nivolumab versus placebo | OS | 336 | 0–1 | 28/03/17 | NCT03063450 |
Cis-pem, cisplatin and pemetrexed; OS, overall survival; p-pem, platinum (cisplatin or carboplatin) and pemetrexed; PS, performance status; pts, patients; RCT, randomized controlled trial.